Company Overview
SRx Health Solutions Inc. operates through its subsidiaries as a specialized provider in the specialty pharmacy sector alongside a dedicated pet health and wellness business line. The company targets customers in the United States, Taiwan, and international markets, offering pet health and wellness products that include kibble, canned food, and freeze-dried raw food. It functions within the Consumer Defensive sector and specifically the Packaged Foods industry, positioning itself to provide essential nutritional goods and pharmacy services that generally maintain demand regardless of economic cycles. With a market capitalization of $42.24M, annual revenue of $9.34M, and an employee count of 10, the company represents a small-cap entity with a highly concentrated operational footprint. These valuation and revenue figures indicate that SRx Health Solutions is a micro-cap enterprise operating with a lean workforce, suggesting a business model that relies heavily on high-margin niche products or specific service contracts rather than broad-scale distribution networks typical of larger packaged food competitors.
Financial Health
The company reported trailing twelve-month revenue of $9.34M, yet recorded a net income of -$17,253,000 and an EBITDA of -$12,770,000, revealing a severe disconnect between top-line generation and profitability. The massive gap between the $9.34M revenue and the -$17.25M net loss highlights an aggressive cost structure or significant one-time expenses that have overwhelmed the entire revenue base, resulting in a negative operating environment. While the company holds $13.06M in cash, it carries $21.03M in debt, creating a liquidity constraint where liabilities exceed liquid assets. The cash-on-hand figure of $13.06M is insufficient to cover the total debt load of $21.03M without refinancing or additional capital raising, indicating a leveraged balance sheet that relies on continued cash flow generation to meet obligations. The debt-to-equity ratio stands at 596.71, which signifies extreme financial leverage and a high risk profile typical of early-stage or distressed growth companies rather than established mature firms. The current ratio is 0.80, meaning the company's current assets are less than its current liabilities, indicating potential short-term liquidity challenges if cash inflows do not accelerate immediately. Return on Equity and Return on Assets are both listed as N/A, which suggests that traditional profitability metrics relative to shareholder equity or total assets are not currently meaningful due to the negative equity or asset base resulting from the net losses.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both N/A, reflecting the fact that the company is currently unprofitable and therefore cannot be valued using standard earnings-based multiples. Because the P/E metrics are unavailable, investors must rely on alternative valuation drivers such as the price-to-book ratio, which is -1.11, indicating the stock is trading below its book value per share. A negative price-to-book ratio often occurs when a company has accumulated significant liabilities or losses that reduce the tangible net worth of the firm below zero. The price-to-sales ratio is 4.52, while the EV/EBITDA is -4.47, suggesting that the market is pricing the stock based on its sales potential and asset base rather than current earnings power. The 52-week high is $2.02 and the 52-week low is $0.08, placing the current trading price within a wide volatility range that spans over 24 times the low. Without a specific current price to calculate the exact percentage, the range indicates significant price discovery and speculative interest rather than stable value anchoring. The beta value is N/A, meaning there is insufficient data to determine the stock's volatility relative to the broader market, which is common for small-cap stocks with lower trading volumes.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, indicating that the company is either too recent to a reporting cycle or that the data is not sufficiently consistent to calculate year-over-year percentage changes. In the absence of growth rates, the financial focus shifts entirely to income generation rather than expansion, as the company currently lacks positive earnings to fuel organic growth or pay dividends. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute any earnings to shareholders, which is a standard practice for unprofitable entities that must retain capital to fund operations. Since the payout ratio is zero and there are no dividends, the company effectively reinvests all available cash flow, if any, back into the business to attempt to restore profitability and stabilize its balance sheet. The overall growth and income profile is characterized by a lack of historical earnings data and zero dividend distribution, focusing purely on survival and potential future operational turnaround.